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Abstract
Background
The extent that controlled diabetes impacts upon mortality, compared with uncontrolled dia-
betes, and how pre-diabetes alters mortality risk remain issues requiring clarification.
Methods
We carried out a cohort study of 22,106 Health Survey for England participants with a
HbA1C measurement linked with UK mortality records. We estimated hazard ratios (HRs) of
all-cause, cancer and cardiovascular disease (CVD) mortality and 95% confidence intervals
(CI) using Cox regression.
Results
Average follow-up time was seven years and there were 1,509 deaths within the sample.
Compared with the non-diabetic and normoglycaemic group (HbA1C <5.7% [<39mmol/
mol] and did not indicate diabetes), undiagnosed diabetes (HbA1C 6.5% [48mmol/mol]
and did not indicate diabetes) inferred an increased risk of mortality for all-causes (HR 1.40,
1.09–1.80) and CVD (1.99, 1.35–2.94), as did uncontrolled diabetes (diagnosed diabetes
and HbA1C 6.5% [48mmol/mol]) and diabetes with moderately raised HbA1C (diag-
nosed diabetes and HbA1C 5.7-<6.5% [39-<48mmol/mol]). Those with controlled diabetes
(diagnosed diabetes and HbA<5.7% [<39mmol/mol]) had an increased HR in relation to
mortality from CVD only. Pre-diabetes (those who did not indicate diagnosed diabetes and
HbA1C 5.7-<6.5% [39-<48mmol/mol]) was not associated with increased mortality, and
raised HbA1C did not appear to have a statistically significant impact upon cancer mortality.
Adjustment for BMI and socioeconomic status had a limited impact upon our results. We
also found women had a higher all-cause and CVD mortality risk compared with men.
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We found higher rates of all-cause and CVD mortality among those with raised HbA1C, but
not for those with pre-diabetes, compared with those without diabetes. This excess differed
by sex and diabetes status. The large number of deaths from cancer and CVD globally sug-
gests that controlling blood glucose levels and policies to prevent hyperglycaemia should
be considered public health priorities.
Introduction
The World Health Organization estimates that annually 3.4 million deaths are due to high lev-
els of glucose in the blood.[1] The prevalence of diabetes, the disease most closely associated
with chronic hyperglycaemia, currently totals 366 million worldwide and this figure is expected
to rise to over 550 million by 2030.[2] In England, around 3.1 million adults over the age of 16
are estimated to be living with diabetes, equating to 7.4% of the population, and the Association
of Public Health Observatories projected that this will increase to 4.6 million (9.5%) by 2030.
[3] Glycated haemoglobin (HbA1C) is a reliable biomarker of long term blood glucose levels.
The International Expert Committee recommended in 2009 that HbA1C is appropriate for the
clinical diagnosis of diabetes: with HbA1C levels 6.5% (48 mmol/mol) being indicative of
diabetes, and HbA1C between 5.7-<6.5% (39 and <48mmol/mol) indicating a pre-diabetic
state within which an individual is at a high risk of developing diabetes.[4]
There is heterogeneity within the results of studies which have sought to explore the associa-
tions between raised HbA1C and all-cause mortality; with some finding an increased risk of
mortality when compared with those who are normoglycaemic, while others demonstrate no
difference[5–9]. The evidence is suggestive of a continuous association between HbA1C and
cardiovascular disease (CVD), including for myocardial infarction and stroke.[10,11] Khaw
et al. found that the association between HbA1C and mortality from all-causes and cardiovas-
cular disease was not only continuous but occurred at measurements lower than the diabetic
threshold.[12] A small number of published epidemiological studies have focussed upon
HbA1C and cancer mortality, with the majority demonstrating a positive association between
the two,[13–15] although some did not.[16] Joshu et al. found that women with raised HbA1C
were at an increased risk of both cancer incidence and mortality, but this association was not
present for men.[14]
There is also inconsistency in current research in a number of areas related to HbA1C and
mortality, including whether there are differences in excess mortality related to HbA1C be-
tween the sexes,[17–20] whether HbA1C begins to impact upon mortality within the normo-
glycaemic range,[17,21,22] how raised HbA1C impacts upon mortality among those with and
without diagnosed diabetes—the latter being an indicator of how well an individual is control-
ling their diabetes,[22] and how it might impact upon mortality from site-specific cancers.
[17,19,21] The impact that socioeconomic status has upon the excess mortality experienced by
those with raised HbA1C/diagnosed diabetes has also yet to be fully assessed.[23]
We explored the associations between raised HbA1C (within both the pre-diabetic and dia-
betic ranges) and mortality from all-causes, cancer and CVD. The impact of confounding fac-
tors, such as BMI and socioeconomic status, upon the associations were also assessed. Finally,
in order to evaluate whether raised HbA1C and diabetes impart mortality risks that differ be-
tween men and women, we performed sex-stratified analyses.
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Participants and data
We linked data from 22,106 participants of the Health Survey for England (HSE) (survey years
2003, 2004, 2005, 2006 and 2008) with a valid HbA1C measurement with UK national mortali-
ty data up to March 2013. Detailed descriptions of the HSE have been published previously.
[24,25] Each year the HSE surveys a new, nationally-representative, random sample of the pop-
ulation utilising a multistage stratified design. Stage one of the HSE involves an interview with-
in which information is sought about the participant’s health and lifestyle, and objective
measurements of weight and height are taken. This is then followed by a visit from a nurse who
collects information about medication use and takes further measurements and samples—
including blood from which HbA1C was measured. Analysis of the HbA1C samples took place
using the Tosoh G7 analyser calibrated to Diabetes Control and Complications Trial (DCCT)
standards.[26] In total, 72% of men and 67% of women who took part in the nurse survey gave
a valid non-fasting blood sample.[27]
Within the current study, an HbA1C measurement of 6.5% (48mmol/mol) was considered
indicative of the presence of diabetes, while a measurement of 5.7 to <6.5% (39 to <48mmol/
mol) indicated pre-diabetes. These cut-off points are those recommended by the World Health
Organization for the clinical diagnosis of diabetes, although in some instances a secondary
measurement may also be required.[28] Diagnosed diabetes was ascertained using self-reported
doctor diagnosed diabetes and/or recorded use of diabetic medicine during the nurse visit. We
used this information, combined with the International Expert Committee’s diabetes and pre-
diabetes categories, to create the following categorisation for those without diagnosed diabetes:
- Normoglycaemic/no diabetes: those who neither indicated diabetes nor had a raised
HbA1C measurement (<5.7% (<39mmol/mol))
- Pre-diabetes: those without diabetes but an HbA1C measurement within the pre-diabetic
range (5.7-<6.5% (39-<48mmol/mol))
- Undiagnosed diabetes: those with raised HbA1C (6.5% (48mmol/mol)) without
diagnosed diabetes.
The following categories were produced for individuals who indicated diagnosed diabetes:
- Controlled diabetes: those with diabetes and an HbA1C <5.7% (<39mmol/mol).
- Diabetes and moderately raised HbA1C: those with diagnosed diabetes and an HbA1C
5.7-<6.5% (39-<48mmol/mol).
- Uncontrolled diabetes: those with diagnosed diabetes and raised (6.5% (48mmol/
mol)) HbA1C.
Smoking was categorised into non-regular-smokers, current and ex-smokers. The socioeco-
nomic status (SES) variable used the Registrar-General’s Social Class categories based on occu-
pation (I: Professional occupations, II: Managerial and technical, IIINM: Skilled non-manual,
IIIM: Skilled manual, IV: Partly-skilled, V: Unskilled and other) were used. BMI (body mass
index, based on measured height and weight) was included within the regression model as a
continuous variable.
Variables were created for mortality from all-causes, as well as cancer (ICD9 codes 140–208;
ICD10 codes C00-C97) and cardiovascular disease (390–459; I00-I99). Mortality data were cat-
egorised and linked to the HSE data by NatCen Social Research. Date of death was provided by
quarter of a year and date of participation within the survey by month.
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and have given written consent for their participation within the HSE and for their data to be
linked within national mortality records -80 to 95% of participants gave consent for this link-
age. No children were included within the study, so consent was not required for their partici-
pation. Mortality records were available only for deaths that occurred within the UK. Ethical
approval was obtained from the National Research Ethics Services.
Statistical analysis
We used Cox regression to estimate models of the associations between glucose metabolism
status and mortality. We adjusted our models for age, sex and smoking status. To assess the im-
pact of socioeconomic status and overweight and obesity on the examined associations we pro-
gressively adjusted our models for socioeconomic status and BMI (as detailed above). Primary
outcome measures were mortality from all-causes, cancer and CVD. All analyses were under-
taken using SPSS V. 20 (SPSS Inc.). Follow-up time was defined as the period of time from the
date of interview to either the end of the study period (March, 2013) or mortality as recorded
within the data.
Results
Characteristic of the study sample
In total, 22,106 individuals aged 16 years within the HSE had a valid measurement for
HbA1C. The average number of follow-up years was 7 (±SD 2.2). 54% of the sample were
women. The sample was evenly split between never regular cigarette smokers and ex or current
smokers. 15,476 (70) had neither a raised HbA1C measurement nor diagnosed diabetes (see
Table 1). Among those who reported diagnosed diabetes, 732 were in the uncontrolled diabetes
category (HbA1C 48mmol/mol (6.5)), 53 had controlled diabetes (HbA1C <5.7%
(<39mmol/mol)), and 234 had diabetes and moderately raised HbA1C 5.7-<6.5% (39-
<48mmol/mol). Of those without diagnosed diabetes, 15,476 had an HbA1C within the nor-
moglycaemic range 5.7% (<39mmol/mol). This category was used as our reference group. 413
had undiagnosed diabetes (HbA1C 6.5% (48mmol/mol) but no diagnosis of diabetes) and
5,198 had pre-diabetes (HbA1C 5.7-<6.5% (39mmol/mol-<48mmol/mol) and no diagnosis of
diabetes). Those with raised HbA1C tended to be older than those with a lower measurement;
for example the mean age of those within the normoglycaemic range, and who did not report
diabetes, was 47 years (±SD 0.14), while among those with uncontrolled diabetes the mean age
was 64 (0.50). BMI was raised among those in either the diabetic or pre-diabetic groups when
compared with those who were normoglycaemic.
1,509 participants (6.8% of the sample) had died by the end of the follow-up period; 506
participants had died of CVD and 466 from cancer.
All-cause mortality
Compared with those without diabetes, participants with undiagnosed, uncontrolled, or diabe-
tes with moderately raised HbA1C had an increased HR in relation to all-cause mortality; al-
though those with pre-diabetes or controlled diabetes did not (see Table 2). When the analyses
were stratified by sex, women who had either undiagnosed or uncontrolled diabetes were at an
increased risk of all-cause mortality 1.61 (1.12–2.30) and 2.27 (1.72–3.01), respectively) while
only men with uncontrolled diabetes were found to have an increased HR (1.62, 1.27–2.05)
(Table 3). Results were not significantly altered by adjustment for SES and BMI. Fig. 1
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Total sample 22,106
Age: mean (SD) 52 (17.7)
Sex (%)
Male 10,198 (46)
Female 11,908 (54)
Smoking status (%)
Never regular 11,184 (51)
Current 4,489 (20)
Ex-regular 6,400 (29)
Missing 33 (<1)
HbA1C: mean (SD) 5.52 (0.74)
HbA1C: mean (SD) by diabetes category: n (%)
Non-diabetic
1 5.22 (0.002)15,476 (70)
Pre-diabetic
2 5.89 (0.003)5,198 (24)
Undiagnosed diabetes
3 7.46 (0.07)413 (2)
Controlled diabetes
4 5.37 (0.03)53 (<1)
Diabetes and moderately raised HbA1C
5 6.10 (0.01)234 (1)
Uncontrolled diabetes
6 8.01 (0.05)732 (3)
BMI: mean (SD) 27 (4.8)
Missing 1160
Social Class (%)
Social Class: I 1,233 (6)
Social Class: II 6,893 (31)
Social Class: IIINM 4,968 (23)
Social Class: IIIM 3,815 (17)
Social Class: IV 3,394 (15)
Social Class: V 1,054 (5)
Other 735 (3)
Missing 14 (<1)
Mortality (%)
Alive 20,597 (93)
Dead 1,509 (7)
Cause of death (%)
Cancer 466 (2)
CVD 506 (2)
1 Normoglycaemic/no diabetes: those who neither indicated diabetes nor had a raised HbA1C
measurement (<39mmol/mol (<5.7%))
2 Pre-diabetes: those without diabetes but an HbA1C measurement within the pre-diabetic range (39-
<48mmol/mol (5.7-<6.5%)).
3 Undiagnosed diabetes: those with raised HbA1C (48mmol/mol (6.5%)) without diagnosed diabetes
4 Controlled diabetes: those with diabetes and an HbA1C <39mmol/mol (5.7%).
5 Diabetes and moderately raised HbA1C: those with diagnosed diabetes and an HbA1C 39-<48mmol/mol
(5.7–6.49%).
6 Uncontrolled diabetes: those with diagnosed diabetes and raised (48mmol/mol (6.5%)) HbA1C.
doi:10.1371/journal.pone.0119882.t001
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cancer mortality HbA1C and diabetes category.
Cancer and cardiovascular disease mortality
Raised HbA1C and/or diabetes did not confer an increased risk of cancer mortality when com-
pared with those without diabetes; this result was also found within the sex-stratified analyses
(Table 2). Fig. 2 details the survival curves for cancer mortality by HbA1C/diabetes category.
The situation was different for cardiovascular mortality (Table 2). Compared with those
without diabetes, each group categorised as having abnormal HbA1C or diabetes had a statisti-
cally significant excess in mortality from CVD apart from those with pre-diabetes. For each
group (undiagnosed, controlled diabetes, uncontrolled, and those with diabetes and moderately
raised HbA1C) the HRs were substantially increased (1.99 (1.35–2.94), 3.22 (1.32–7.84), 2.63
(1.97–3.51), and 1.89 (1.20–2.97), respectively). The elevation in risk survived adjustment for
SES and BMI. Fig. 3 details the survival curves for CVD mortality by HbA1C/diabetes category.
When the analyses were sex-stratified, we observed a mixed pattern. Women with undiagnosed
or uncontrolled diabetes had an increased risk of mortality from CVD, while for men, con-
trolled diabetes, diabetes with moderately raised HbA1C and uncontrolled diabetes were
Table 2. HRs for all-cause and cause-speciﬁc mortality by glycated haemoglobin and self-reported diabetes category.
n All-cause Cancer CVD
Age, sex & smoking 22,073
No diabetes
1 111
Pre-diabetes
2 0.93(0.83–1.04) 0.88(0.72–1.08) 1.07 (0.88–1.32)
Undiagnosed diabetes
3 1.40(1.09–1.80) 1.46(0.94–2.27) 1.99(1.35–2.94)
Controlled diabetes
4 1.71(0.89–1.04) 0.61(0.09–4.38) 3.22(1.32–7.84)
Diabetes and moderately raised HbA1C
5 1.42(1.07–1.90) 1.03(0.56–1.89) 1.89(1.20–2.97)
Uncontrolled diabetes
6 1.85(1.54–2.22) 1.24(0.85–1.81) 2.63(1.97–3.51)
+ SES 22,060
No diabetes
1 111
Pre-diabetes
2 0.92(0.82–1.03) 0.87(0.70–1.07) 1.07(0.87–1.31)
Undiagnosed diabetes
3 1.38(1.07–1.78) 1.430.92–2.22) 1.98(1.34–2.93)
Controlled diabetes
4 1.69(0.88–3.27) 0.61(0.09–4.38) 3.16(1.30–7.69)
Diabetes and moderately raised HbA1C
5 1.39(1.05–1.85) 1.01(0.55–1.85) 1.84(1.17–2.90)
Uncontrolled diabetes
6 1.80(1.50–2.16) 1.20(0.82–1.75) 2.57(1.93–3.44)
+ BMI 20,906
No diabetes
1 111
Pre-diabetes
5 0.95(0.84–1.08) 0.88(0.71–1.10) 1.06(0.85–1.31)
Undiagnosed diabetes
3 1.51(1.15–1.97) 1.40(0.87–2.26) 2.07(1.37–3.15)
Controlled diabetes
6 1.90(0.98–3.68) 0.67(0.09–4.76) 3.43(1.41–8.37)
Diabetes and moderately raised HbA1C
4 1.41(1.02–1.94) 0.86(0.42–1.74) 1.81(1.10–3.00)
Uncontrolled diabetes
2 1.77(1.44–2.16) 1.19(0.79–1.79) 2.32(1.68–3.22)
1 Normoglycaemic/no diabetes: those who neither indicated diabetes nor had a raised HbA1C measurement (<39mmol/mol (<5.7%))
2 Pre-diabetes: those without diabetes but an HbA1C measurement within the pre-diabetic range (39-<48mmol/mol (5.7-<6.5%)).
3 Undiagnosed diabetes: those with raised HbA1C (48mmol/mol (6.5%)) without diagnosed diabetes
4 Controlled diabetes: those with diabetes and an HbA1C <39mmol/mol (5.7%).
5 Diabetes and moderately raised HbA1C: those with diagnosed diabetes and an HbA1C 39-<48mmol/mol (5.7–6.49%).
6 Uncontrolled diabetes: those with diagnosed diabetes and raised (48mmol/mol (6.5%)) HbA1C.
doi:10.1371/journal.pone.0119882.t002
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betes was particularly striking. None of these results were materially altered by adjustment for
SES or BMI.
Discussion
Our study demonstrated an excess in mortality from all-causes among those with raised
HbA1C, including within the pre-diabetes range among those with diagnosed diabetes. Raised
HbA1C among people with diabetes was also strongly associated with mortality from CVD, but
not cancer. BMI and socioeconomic status did not affect the associations.
These results support those of Skriver et al. who found increased all-cause mortality among
those with an HbA1C measurement 7% (53 mmol/mol) (HR 1.26 (95% CI 1.15, 1.39)) and a
U-shaped relationship between increasing HbA1C and all-cause mortality.[8] A 2013 study
also found an increased HR in relation to HbA1C and all-cause mortality that was marginally
non-significant (HR 1.21, 95% CI 0.99–1.47).[5] Within the current study, among those with
diabetes only those with raised HbA1C had an increased risk of all-cause mortality, while for
mortality from CVD all diabetes/raised HbA1C categorieshad an increased risk. The only
Table 3. HRs for all-cause and cause-speciﬁc mortality by glycated haemoglobin and diagnosed diabetes category, stratiﬁed by sex.
n
1 All-cause Cancer CVD
Age, sex & smoking 11,89210,181 Women Men Women Men Women Men
No diabetes 1 1 1 1 1 1
Pre-diabetes 0.97(0.82–1.14) 0.90(0.77–1.06) 1.13(0.83–1.54) 0.71(0.53–0.94) 1.09(0.81–1.47) 1.08(0.82–1.43)
Undiagnosed diabetes 1.61(1.12–2.30) 1.25(0.88–1.78) 1.13(0.49–2.59) 1.64(0.98–2.76) 2.78(1.65–4.69) 1.41(0.78–2.57)
Controlled diabetes 1.61(0.66–3.91) 1.76(0.66–4.72) 1.47(0.20–
10.61)
N/A 1.90(0.46–7.77) 4.55(1.44–14.32)
Diabetes and moderately
raised HbA1C
1.38(0.90–2.14) 1.45(0.99–2.12) 1.37(0.55–3.39) 0.85(0.37–1.92) 1.39(0.64–3.01) 2.28(1.30–3.98)
Uncontrolled diabetes 2.27(1.72–3.01) 1.62(1.27–2.05) 1.57(0.84–2.94) 1.08(0.68–1.73) 3.51(2.26–5.45) 2.24 (1.53–3.28)
+SES 11,88110,166
No diabetes 1 1 1 1 1 1
Pre-diabetes 0.95(0.80–1.11) 0.89(0.75–1.04) 1.10(0.81–1.50) 0.69(0.52–0.92) 1.08(0.80–1.46) 1.08(0.81–1.42)
Undiagnosed diabetes 1.54(1.07–2.20) 1.26(0.88–1.79) 1.06(0.46–2.43) 1.69(1.01–2.84) 2.71(1.60–4.58) 1.42(0.78–2.58)
Controlled diabetes 1.60(0.66–3.90) 1.67(0.62–4.48) 1.49(0.21–
10.76)
N/A 1.80(0.44–7.38) 4.41(1.40–13.90)
Diabetes and moderately
raised HbA1C
1.32(0.85–2.03) 1.46(1.00–2.13) 1.28(0.52–3.16) 0.87(0.38–1.97) 1.34(0.62–2.92) 2.25(1.29–3.94)
Uncontrolled diabetes 2.19(1.66–2.90) 1.57(1.23–1.99) 1.48(0.79–2.77) 1.04(0.65–1.67) 3.42(2.22–5.32) 2.19(1.50–3.21)
+ BMI 11,1969,698
No diabetes 1 1 1 1 1 1
Pre-diabetes 0.99(0.83–1.18) 0.92(0.77–1.09) 1.11(0.80–1.53) 0.71(0.53–0.97) 1.06(0.76–1.46) 1.08(0.81–1.45)
Undiagnosed diabetes 1.71(1.16–2.51) 1.35(0.93–1.97) 1.16(0.50–2.70) 1.60(0.90–2.84) 2.67(1.51–4.72) 1.58(0.85–2.97)
Controlled diabetes 1.87(0.76–4.56) 1.87(0.70–5.01) 1.66(0.23–
11.98)
N/A 2.04(0.49–8.45) 4.90(1.55–15.50)
Diabetes and moderately
raised HbA1C
1.46(0.90–2.37) 1.37(0.90–2.10) 1.53(0.61–3.81) 0.50(0.16–1.57) 1.23(0.49–3.06) 2.27(1.24–4.16)
Uncontrolled diabetes 2.25(1.65–3.09) 1.52(1.16–1.98) 1.38(0.69–2.78) 1.06(0.64–1.75) 3.40(2.08–5.52) 1.90(1.23–2.95)
1The ﬁrst number relates to the total number of women included in the analyses, while the second relates to the number of men.
doi:10.1371/journal.pone.0119882.t003
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under investigation; this result contradicts those of a recent meta-analysis, which found associ-
ations between pre-diabetes and mortality from all-causes and CVD, suggesting the need for
further analyses in this area.[29]
Fig 1. Fully adjusted (age, sex, smoking, SES and BMI) all-cause mortality survival curves by HbA1C
and diabetes category (whole sample).
doi:10.1371/journal.pone.0119882.g001
Fig 2. Fully adjusted survival curves for cancer mortality by HbA1C and diabetes category (whole
sample).
doi:10.1371/journal.pone.0119882.g002
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more strongly associated with mortality from all-causes and CVD rather than cancer.[5,10,15]
Compared with normoglycaemic participants, those with raised HbA1C and/or diabetes (un-
controlled, undiagnosed or with a moderately raised HbA1C) had an increased risk of mortality
from all-causes and CVD; those with controlled diabetes had an increased risk of CVD mortali-
ty only. Earlier studies found that impaired glucose metabolism impacts upon CVD mortality
for women to a greater extent than for men[30]; our results indicate differences in risk by sex
dependent upon HbA1C/diabetes category analysed.
We found HbA1C and diabetes were not significantly associated with cancer mortality, al-
though an earlier cohort study found a 1mmol/l increment in glucose increased the risk of fatal
cancer for both men (1.15, 1.07–1.22) and women (1.21, 1.11–1.33).[18] Joshu et al. also found
that raised HbA1C was not associated with increased cancer mortality among men, but was
among women.[31] Research able to utilise larger datasets with a greater number of cancer
mortality endpoints is needed to further assess the association between HbA1C and cancer
mortality. One reason for the lack of association between HbA1C and cancer mortality within
our results, but found in those of earlier studies, may be the differing rates of site-specific can-
cers within the all-cancers outcome variable used within each study. Although limited in num-
ber, previous studies have suggested that increased blood glucose is associated with increased
mortality from a number of site-specific cancers, but is not associated with others.[32] There-
fore results related to a grouped, all-cancers variable may be concealing differences in site-spe-
cific cancer mortality risk. Further research is required which explores the associations
between HbA1C and site-specific cancer mortality and incidence. The larger sample size uti-
lised by Stocks et al.,[18] and the longer follow-up time and corresponding greater number of
cancer deaths in the research undertaken by Joshu et al.,[31] compared with our study may
also have given these studies the power needed to find a small, statistically significant
Fig 3. Fully adjusted survival curves for CVD mortality by HbA1C and diabetes category (whole
sample).
doi:10.1371/journal.pone.0119882.g003
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study suggested that our analyses were not underpowered, future studies which are able to uti-
lise larger samples and investigate the sex differences within the associations between impaired
glucose metabolism and mortality are required.
A number of plausible pathways have been proposed for the relationship between HbA1C,
diabetes and cause-specific mortality. Increased rates of atherosclerosis appear to explain much
of the association between diabetes and cardiovascular disease; raised HbA1C has been found
to be strongly associated with carotid intima-media thickness, a marker of atherosclerosis.
[33,34]. Although the epidemiological evidence related to HbA1C and cancer is limited, the key
biological causal factors relate to the anti-apoptotic, proliferative and mitogenic nature of insu-
lin and insulin-like growth factor (IGF) and the impact that hyperglycaemia has upon mortali-
ty risk.[35–37] If a causal association were to be found between raised HbA1C and mortality
from CVD and other causes then some of the differences found in mortality between those
with and without diabetes could be overcome through stricter glycaemic control. At the same
time the potential deleterious impact of tighter control—for example the increased mortality
found within the strict glucose control group of the Action to Control Cardiovascular Risk in
Diabetes (ACCORD) study and the risk of hypoglycaemia [9,38–40]—would have to be bal-
anced against any such reductions in mortality and take into account the specific characteris-
tics of each individual with raised blood glucose.[9,41]
A strength of this study was its utilisation of a nationally-representative, general population
sample of over 22,000 participants with a recorded HbA1C measurement and comprehensive
linked mortality data. The use of HSE data enabled the inclusion of a detailed HbA1C and self-
reported diabetes variable and a range of confounding factors within the analyses. Further, un-
like a number of studies which have utilised only self-reported diabetes as an indicator of the
presence of the disease, this study used a valid measure of HbA1C to explore the association be-
tween diabetes, blood glucose and mortality. The recording of the use of diabetes-related medi-
cations, within the nurse visit, also enabled the further verification of diagnosed
diabetes information.
The majority of the study sample self-identified as white—around 85%—a similar percent-
age to the general, free-living population of England.[42] Although the results of earlier analy-
ses (not shown) were suggestive of ethnicity not having a significant impact upon the excess
mortality found among those with raised HbA1C/diabetes, the small number of deaths among
those from Black and Minority Ethnic populations and the corresponding lack of power made
interpretation of the results difficult. Studies utilising larger datasets, with a corresponding
larger number of mortality endpoints, could further explore the impact of ethnicity.
The current study did not assess the impact that the use of different types of diabetes-related
medications may have upon the excess risk experienced by those with diabetes. Those with dia-
betes may change drug regimens regularly and may switch from oral medications to insulin as
their disease progresses. Because of this, research in this area favours the use of randomised
controlled trials to explore this issue further.
Our results demonstrate that diabetes/raised HbA1C are associated with mortality from
CVD and all-causes. This result was found among those with and without diagnosed diabetes
and, if confirmed, suggests that the monitoring of impaired blood glucose could be an impor-
tant tool in relation to reducing mortality from these causes. The results also support the in-
troduction of clinical practices which aim to prevent and detect pre-diabetes, diagnose
previously undiagnosed diabetes, and optimise HbA1C levels among people with diagnosed
diabetes.
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This study—utilising data from a nationally representative sample—demonstrates an associa-
tion between HbA1C and all-cause and cardiovascular disease mortality among those with and
without diagnosed diabetes that remains after adjustment for a range of confounding factors
including adiposity. If these result were to be replicated within further studies, the lowering of
HbA1C within populations could become an important public health goal.
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